{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T09:45:02Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 22.2, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09500-48c2-71e2-8310-a2774899874a\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: fleroxacin\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 regi", "usd": 0.0, "recall": true }, "codex": { "seconds": 83.9, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09500-48ba-76a2-a78e-e6d031cb918b\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: fleroxacin\nRegistry id: vr.tr.fleroxacin\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nCo" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:48:58+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:30+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q3746573", "registryId": "vr.tr.fleroxacin", "name": "fleroxacin", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q3746573/", "model": { "registry_id": "vr.tr.fleroxacin", "name": "fleroxacin", "purpose": "Enable an agent to identify fleroxacin, assess the condition and suitability of a material sample, and determine which handling or use decisions its evidence supports.", "definition": "Fleroxacin is a synthetic trifluorinated fluoroquinolone antibacterial substance that inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication.", "scope_statement": "This model owns fleroxacin as the chemical substance registered as vr.tr.fleroxacin in PHY / PHY.MAT, including molecular identity, material forms, quality, physicochemical behaviour, antibacterial activity evidence, and substance-level restrictions.", "in_scope": [ "Molecular identity and distinction from other fluoroquinolones", "Parent substance, salt and solvate relationships, with explicit composition boundaries", "Sample purity, assay basis, impurities and analytical identity", "Physical state, solubility, ionisation and stability under recorded conditions", "Fleroxacin-specific antibacterial activity and resistance evidence", "Chemical handling hazards and jurisdiction-specific substance status" ], "out_of_scope": [ "Finished medicines, brands, excipients and dosage-form performance", "Patient diagnosis, prescribing and individual dosing decisions", "Manufacturing plant design and synthesis process execution", "Bacterial species and resistance mechanisms as independent entities", "General fluoroquinolone properties without fleroxacin-specific applicability", "Environmental treatment facilities and waste-management operations" ], "distinguishing_features": [ "Match the molecular connectivity to a quinolone bearing 6,8-difluoro, N1-(2-fluoroethyl) and C7-(4-methylpiperazin-1-yl) substituents; the antibiotic class alone is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Fleroxacin)", "Cross-check the parent identity against CAS 79660-72-3 and PubChem CID 3357; a supplier name or brand does not establish identity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Fleroxacin)", "Check consistency with parent formula C17H18F3N3O3 and molar mass 369.34 g/mol, while requiring structural evidence to exclude isomers. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Fleroxacin)", "Distinguish parent fleroxacin from its hydrochloride: PubChem lists 79660-53-0 as a related hydrochloride CAS number, so counterion and assay basis must be checked. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Fleroxacin)" ], "characteristics": [ { "name": "Chemical identity", "kind": "relation", "unit_or_values": "Registry identifier linked to verified structure, CAS record and chemical database record", "why_it_matters": "Prevents substitution by a similarly named fluoroquinolone or a related salt." }, { "name": "Material form", "kind": "category", "unit_or_values": "Parent substance, specified salt, hydrate, solvate or unresolved form", "why_it_matters": "Determines which formula mass, composition and property measurements apply." }, { "name": "Fleroxacin content", "kind": "measurement", "unit_or_values": "% mass fraction or mg/g; as-is, dry or parent-equivalent basis; method and uncertainty", "why_it_matters": "Supports defensible concentration calculations and sample acceptance." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "Named and unknown impurities in % or mg/kg, with detection and quantification limits", "why_it_matters": "Separates fleroxacin content from degradation products, residual solvents and other contaminants." }, { "name": "Physical and solid-state condition", "kind": "state", "unit_or_values": "Phase, crystallinity, identified solid form and water content at stated temperature and pressure", "why_it_matters": "Conditions dissolution, storage behaviour and comparability between samples." }, { "name": "Ionisation and solubility", "kind": "measurement", "unit_or_values": "pKa and equilibrium solubility in mg/mL or mol/L, with pH, solvent, temperature and method", "why_it_matters": "Supports solution preparation without assuming that values transfer between media." }, { "name": "Thermal behaviour", "kind": "measurement", "unit_or_values": "Melting, transition or decomposition temperature in °C with method; boiling point only if established", "why_it_matters": "Distinguishes measured transitions from unsupported heating or volatility assumptions." }, { "name": "Stability under exposure", "kind": "measurement", "unit_or_values": "Remaining assay and degradant formation versus time, light, temperature, humidity and solution conditions", "why_it_matters": "Determines whether stored material or prepared solutions remain suitable." }, { "name": "Antibacterial activity", "kind": "measurement", "unit_or_values": "MIC in mg/L or target inhibition endpoint, with organism or enzyme, method and conditions", "why_it_matters": "Keeps measured activity distinct from class membership or assumed clinical effectiveness." }, { "name": "Hazard and permitted-use status", "kind": "relation", "unit_or_values": "Applicable SDS, GHS classification, exposure-limit source and regulatory record, each dated and scoped", "why_it_matters": "Connects handling and use decisions to the actual material and jurisdiction." } ], "affordances": [ "Reconcile a fleroxacin-labelled sample with structural identifiers and supporting analytical evidence.", "Calculate parent-equivalent content or solution concentration from verified form, assay and water content.", "Assess whether a lot meets a stated analytical, research or pharmaceutical material specification.", "Select supported preparation and storage conditions from fleroxacin-specific measurements.", "Compare antibacterial measurements only after aligning organisms, methods and concentration bases.", "Determine supported handling, segregation and disposal actions from applicable hazard and regulatory evidence." ], "agent_conduct": { "may": [ "Describe fleroxacin's class, mechanism and historical clinical use from authoritative sources.", "Flag that fluoroquinolones carry serious class warnings when a person asks about them." ], "must_not": [ "Recommend, dose or supply fleroxacin to a person without a prescriber's decision.", "Advise taking it for viral infections or without a confirmed need.", "Downplay tendon, nerve or photosensitivity reactions reported with this class.", "Help obtain it outside lawful supply channels." ], "requires_human": [ "Any decision to start, stop or change antibiotic treatment." ] }, "ethics": { "considerations": [ "Unnecessary antibiotic use drives resistance that harms people who never took the drug.", "Patients deserve clear warnings about rare but disabling side effects." ], "affected_parties": [ "Patients", "Communities exposed to resistant bacteria", "Prescribers" ] }, "owners": { "steward": "The marketing authorisation holder where it is licensed; the prescriber answers for each use.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identity cannot be settled by sight; tablets or solutions must be confirmed by label, batch and pharmacy records." ], "failure_modes_and_hazards": [ "Fluoroquinolones can cause tendon damage, nerve damage and central nervous system effects.", "Fleroxacin was associated with notable phototoxic skin reactions.", "Misuse selects for quinolone-resistant bacteria." ], "what_it_is_for": [ "Fleroxacin is encountered in antibacterial pharmacology, pharmaceutical analysis and research on fluoroquinolone activity.", "Reference materials and pharmaceutical samples are used to investigate chemical identity, purity and antibacterial properties." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification maintained by the World Health Organization Collaborating Centre for Drug Statistics Methodology assigns fleroxacin code J01MA08 within fluoroquinolone antibacterials." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q3746573: fleroxacin", "url": "https://www.wikidata.org/wiki/Q3746573", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Fleroxacin", "url": "https://en.wikipedia.org/wiki/Fleroxacin", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "fleroxacin-identity-and-form", "name": "Fleroxacin identity and form", "description": "Establish which molecular entity and material form the name denotes.", "rationale": "Fluoroquinolone names, related salts and product labels cannot substitute for chemical identification.", "layers": [ { "id": "molecular-recognition", "name": "Molecular recognition", "description": "Resolve fleroxacin through structure and traceable identifiers.", "findings": [ { "id": "structure-identifier-agreement", "name": "Structure-identifier agreement", "description": "Require agreement between the fleroxacin structure, identifier records and sample identity evidence.", "questions": [ { "text": "Does the recorded structure contain fleroxacin's 6,8-difluoro, 2-fluoroethyl and methylpiperazinyl substitution pattern?", "kind": "definition", "id": "structure-identifier-agreement-q01" }, { "text": "Which inspected identifier records and analytical results support assigning this material to vr.tr.fleroxacin?", "kind": "provenance", "id": "structure-identifier-agreement-q02" } ] } ] }, { "id": "parent-and-associated-forms", "name": "Parent and associated forms", "description": "Separate molecular identity from counterions, associated solvent and formulated mixtures.", "findings": [ { "id": "form-and-content-basis", "name": "Form and content basis", "description": "Record the supplied form and the relationship between weighed material and fleroxacin content.", "questions": [ { "text": "Is the sample parent fleroxacin, a specified salt, a hydrate or solvate, or a mixture containing fleroxacin?", "kind": "boundary", "id": "form-and-content-basis-q01" }, { "text": "What counterion, solvent or water stoichiometry supports conversion to parent-equivalent content?", "kind": "measurement", "id": "form-and-content-basis-q02" } ] } ] } ] }, { "id": "fleroxacin-quality-and-analysis", "name": "Fleroxacin quality and analysis", "description": "Assess sample identity, content and unwanted constituents against an intended use.", "rationale": "An antibiotic name and nominal purity do not establish that a lot is analytically reliable or fit for use.", "layers": [ { "id": "identity-and-assay", "name": "Identity and assay", "description": "Connect identity confirmation and quantitative assay to suitable reference evidence.", "findings": [ { "id": "specific-and-traceable-assay", "name": "Specific and traceable assay", "description": "Require methods that distinguish fleroxacin from relevant neighbouring compounds and report a clear assay basis.", "questions": [ { "text": "Which orthogonal methods confirm fleroxacin identity rather than relying only on chromatographic retention time?", "kind": "measurement", "id": "specific-and-traceable-assay-q01" }, { "text": "Which reference standard, calibration and assay basis support the reported fleroxacin content?", "kind": "provenance", "id": "specific-and-traceable-assay-q02" } ] } ] }, { "id": "impurities-and-acceptance", "name": "Impurities and acceptance", "description": "Evaluate contaminants and degradation products against a use-specific specification.", "findings": [ { "id": "lot-suitability", "name": "Lot suitability", "description": "Distinguish a research reagent, analytical standard and pharmaceutical material through documented quality requirements.", "questions": [ { "text": "Which related substances, residual solvents, water and unknown impurity peaks were measured, and at what limits?", "kind": "measurement", "id": "lot-suitability-q01" }, { "text": "Which documented specification permits accepting this fleroxacin lot for the proposed use?", "kind": "action", "id": "lot-suitability-q02" } ] } ] } ] }, { "id": "fleroxacin-physical-behaviour", "name": "Fleroxacin physical behaviour", "description": "Describe the material under explicit solid-state, solution and thermal conditions.", "rationale": "Preparation and measurement depend on form and medium; a single unqualified property value can mislead.", "layers": [ { "id": "solid-state-and-thermal-response", "name": "Solid state and thermal response", "description": "Characterise the starting solid and its response to heating.", "findings": [ { "id": "form-dependent-transitions", "name": "Form-dependent transitions", "description": "Associate thermal observations with the tested fleroxacin form and distinguish melting from decomposition.", "questions": [ { "text": "What diffraction, water-content or thermal evidence identifies the tested solid form?", "kind": "measurement", "id": "form-dependent-transitions-q01" }, { "text": "Does the reported thermal event represent melting, solvent loss, another transition or decomposition, and under which conditions?", "kind": "measurement", "id": "form-dependent-transitions-q02" } ] } ] }, { "id": "solution-speciation-and-preparation", "name": "Solution speciation and preparation", "description": "Relate ionisation and dissolution to a specified preparation medium.", "findings": [ { "id": "conditioned-solubility", "name": "Conditioned solubility", "description": "Require solvent, pH, temperature and equilibration details before using a fleroxacin solubility value.", "questions": [ { "text": "Which measured pKa and equilibrium-solubility values apply to this form in the intended medium?", "kind": "measurement", "id": "conditioned-solubility-q01" }, { "text": "What preparation conditions achieve the target dissolved concentration, and how is precipitation checked?", "kind": "action", "id": "conditioned-solubility-q02" } ] } ] } ] }, { "id": "fleroxacin-stability-and-handling", "name": "Fleroxacin stability and handling", "description": "Determine whether exposure history preserves composition and supports safe handling.", "rationale": "Bulk material and prepared solutions need distinct evidence for continued suitability and handling controls.", "layers": [ { "id": "exposure-and-degradation", "name": "Exposure and degradation", "description": "Track changes under storage and experimental conditions.", "findings": [ { "id": "supported-storage-window", "name": "Supported storage window", "description": "Base storage and solution-use windows on measured fleroxacin loss and impurity formation.", "questions": [ { "text": "What fleroxacin-specific data quantify effects of light, temperature, humidity and solution pH on assay and degradants?", "kind": "measurement", "id": "supported-storage-window-q01" }, { "text": "Does the sample's exposure history remain within the tested conditions, or is reanalysis required?", "kind": "action", "id": "supported-storage-window-q02" } ] } ] }, { "id": "chemical-hazards-and-disposal", "name": "Chemical hazards and disposal", "description": "Apply evidence for the supplied substance or mixture to laboratory handling and waste.", "findings": [ { "id": "applicable-handling-controls", "name": "Applicable handling controls", "description": "Distinguish material hazard classification from clinical adverse-effect information.", "questions": [ { "text": "Which current SDS and jurisdictional classifications apply to this fleroxacin form and concentration, and are exposure limits established?", "kind": "provenance", "id": "applicable-handling-controls-q01" }, { "text": "What containment, protective equipment and antibiotic-waste route follow from those records and the proposed operation?", "kind": "action", "id": "applicable-handling-controls-q02" } ] } ] } ] }, { "id": "fleroxacin-activity-and-use-boundaries", "name": "Fleroxacin activity and use boundaries", "description": "Connect antibacterial evidence and regulatory records to appropriately bounded uses.", "rationale": "Chemical identity establishes neither susceptibility of a particular organism nor permission to use a material therapeutically.", "layers": [ { "id": "antibacterial-evidence", "name": "Antibacterial evidence", "description": "Separate molecular-target evidence from organism-level susceptibility.", "findings": [ { "id": "target-and-susceptibility-context", "name": "Target and susceptibility context", "description": "Fleroxacin is identified as a fluoroquinolone antibacterial with DNA gyrase and topoisomerase IV inhibitor roles; individual activity claims require experimental context. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Fleroxacin)", "questions": [ { "text": "Which fleroxacin-specific experiments support target inhibition, and which separately establish organism-level antibacterial activity?", "kind": "provenance", "id": "target-and-susceptibility-context-q01" }, { "text": "For each MIC, what strain, resistance phenotype, medium, inoculum, incubation conditions and method were used?", "kind": "measurement", "id": "target-and-susceptibility-context-q02" }, { "text": "Is a fleroxacin-specific interpretive breakpoint available for this organism and method, or must the result remain uninterpreted?", "kind": "boundary", "id": "target-and-susceptibility-context-q03" } ] } ] }, { "id": "regulatory-and-product-relations", "name": "Regulatory and product relations", "description": "Link substance-level records to separately modelled products and authorised uses.", "findings": [ { "id": "jurisdiction-and-use-evidence", "name": "Jurisdiction and use evidence", "description": "Record dated authority evidence without treating historical marketing or supplier availability as current therapeutic authorisation.", "questions": [ { "text": "Which authority records establish fleroxacin's substance identifiers and current status in the relevant jurisdiction?", "kind": "provenance", "id": "jurisdiction-and-use-evidence-q01" }, { "text": "Does the proposed action concern chemical research, material supply or an authorised medicinal product, and which neighbouring model owns its approval requirements?", "kind": "boundary", "id": "jurisdiction-and-use-evidence-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recalled knowledge; no sources were consulted.", "Current authorization, availability and substance-specific prescribing restrictions require jurisdiction-specific verification.", "Solid form, purity specifications, melting behavior, GHS classification and exposure limits are not established here." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of fleroxacin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (WHO)", "value_or_pattern": "fleroxacin", "note": "Names the active substance rather than a branded medicinal product." }, { "scheme": "CAS Registry Number", "value_or_pattern": "79660-72-3", "note": "Identifies fleroxacin; salts and other separately registered forms require their own identity checks." }, { "scheme": "Molecular formula", "value_or_pattern": "C17H18F3N3O3", "note": "Composition of the parent compound; a molecular formula is not a unique substance identifier." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of fleroxacin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Has been used as an antibacterial medicine for susceptible bacterial infections, including urinary tract infections.", "Used in research on fluoroquinolone antibacterial activity, pharmacokinetics and bacterial resistance." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of fleroxacin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of the parent compound", "typical_range": "369.34", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of fleroxacin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Bacterial resistance can undermine activity through changes in target enzymes, reduced drug entry or increased efflux.", "Phototoxicity is a recognized adverse effect.", "Central nervous system adverse effects can include insomnia and dizziness.", "Fluoroquinolone class hazards include tendinitis, tendon rupture and peripheral neuropathy.", "Complex formation with multivalent metal ions can reduce oral absorption." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of fleroxacin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Medicinal authorization, marketed formulations and approved indications depend on jurisdiction and historical period." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of fleroxacin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Fluoroquinolone", "difference": "The antibacterial class to which fleroxacin belongs; fleroxacin is one specific chemical member." }, { "name": "Ciprofloxacin", "difference": "A distinct fluoroquinolone with different substituents and one fluorine atom, whereas fleroxacin has three." }, { "name": "Fleroxacin medicinal product", "difference": "A formulated dosage form containing fleroxacin and potentially excipients; the registered substance is the active chemical itself." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of fleroxacin this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative records establish any EC identifier and current jurisdiction-specific regulatory status for parent fleroxacin and its relevant salts?", "Which solid forms, hydrates or solvates are experimentally established, and what form-specific melting or decomposition data are reliable?", "What measured pKa, solubility and solution-stability data support the intended preparation media and storage conditions?", "Which current fleroxacin-specific GHS classifications, occupational exposure limits, phototoxicity evidence and environmental hazard data are applicable?", "Which validated impurity specifications, susceptibility methods and interpretive breakpoints exist for the intended material and antibacterial use?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 17, "questions": 28 } }